Literature DB >> 18984024

The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.

Silayuv E Bongfen1, Patricia M Ntsama, Sandra Offner, Thomas Smith, Ingrid Felger, Marcel Tanner, Pedro Alonso, Issa Nebie, Jackeline F Romero, Olivier Silvie, Ralph Torgler, Giampietro Corradin.   

Abstract

The N-terminal domain of the circumsporozoite protein (CSP) has been largely neglected in the search for a malaria vaccine in spite of being a target of inhibitory antibodies and protective T cell responses in mice. Thus, in order to develop this region as a vaccine candidate to be eventually associated with other candidates and, in particular, with the very advanced C-terminal counterpart, synthetic constructs representing N- and C-terminal regions of Plasmodium falciparum and Plasmodium berghei CSP were administered as single or combined formulations in mice. We show that the antisera generated against the combinations inhibit sporozoite invasion of hepatocytes in vitro better than antisera against single peptides. Furthermore, two different P. falciparum CSP N-terminal constructs (PfCS22-110 and PfCS65-110) were recognized by serum samples from people living in malaria-endemic regions. Importantly, recognition of the short N-terminal peptide (PfCS65-110) by sera from children living in a malaria-endemic region was associated with protection from disease. Taken together, these results underline the potential of using such fragments as malaria vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18984024     DOI: 10.1016/j.vaccine.2008.09.097

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

1.  Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Authors:  Myriam Arévalo-Herrera; Liliana Soto; Blanca Liliana Perlaza; Nora Céspedes; Omaira Vera; Ana Milena Lenis; Anilza Bonelo; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

Review 2.  Malaria vaccines since 2000: progress, priorities, products.

Authors:  Patrick E Duffy; J Patrick Gorres
Journal:  NPJ Vaccines       Date:  2020-06-09       Impact factor: 7.344

Review 3.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

4.  Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice.

Authors:  Kathrin Kastenmüller; Diego A Espinosa; Lauren Trager; Cristina Stoyanov; Andres M Salazar; Santosh Pokalwar; Sanjay Singh; Sheetij Dutta; Christian F Ockenhouse; Fidel Zavala; Robert A Seder
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

5.  High-density Peptide Arrays Help to Identify Linear Immunogenic B-cell Epitopes in Individuals Naturally Exposed to Malaria Infection.

Authors:  Thomas Jaenisch; Kirsten Heiss; Nico Fischer; Carolin Geiger; F Ralf Bischoff; Gerhard Moldenhauer; Leszek Rychlewski; Ali Sié; Boubacar Coulibaly; Peter H Seeberger; Lucjan S Wyrwicz; Frank Breitling; Felix F Loeffler
Journal:  Mol Cell Proteomics       Date:  2019-01-10       Impact factor: 5.911

6.  Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies.

Authors:  Diego A Espinosa; Gabriel M Gutierrez; Maricarmen Rojas-López; Amy R Noe; Lirong Shi; Sze-Wah Tse; Photini Sinnis; Fidel Zavala
Journal:  J Infect Dis       Date:  2015-03-11       Impact factor: 5.226

7.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

8.  Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint.

Authors:  Michael D Porter; Jennifer Nicki; Christopher D Pool; Margot DeBot; Ratish M Illam; Clara Brando; Brooke Bozick; Patricia De La Vega; Divya Angra; Roberta Spaccapelo; Andrea Crisanti; Jittawadee R Murphy; Jason W Bennett; Robert J Schwenk; Christian F Ockenhouse; Sheetij Dutta
Journal:  Clin Vaccine Immunol       Date:  2013-03-27

9.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

10.  Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate.

Authors:  Matthew L Plassmeyer; Karine Reiter; Richard L Shimp; Svetlana Kotova; Paul D Smith; Darrell E Hurt; Brent House; Xiaoyan Zou; Yanling Zhang; Merrit Hickman; Onyinyechukwu Uchime; Raul Herrera; Vu Nguyen; Jacqueline Glen; Jacob Lebowitz; Albert J Jin; Louis H Miller; Nicholas J MacDonald; Yimin Wu; David L Narum
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.